Preprints Papers of Articles Related to Antibodies and COVID-19

-  Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
- SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
-  Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan–[negative] implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
- Comparative performance of five commercially available serologic assays to detect antibodies to SARS-coV-2 and identify individuals with high neutralizing titers. 

MedRxiv Preprint Papers Related to SARS-CoV-2 Antibody Testing

- Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective 

Antibody Therapeutics Papers Related to Antibodies and COVID-19

- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- Structural basis of a shared antibody response
to SARS-CoV-2

Science Papers Related to Antibodies and COVID-19

- Antibody Therapeutics
-  MedRxiv Preprint Papers
- Preprints
- Science

State University of New York at Stony Brook

Princeton University

Northwestern University

Infection by SARS-CoV-2 triggers the creation of antibodies in a two-part response: 
- early antibodies (IgM)
- late antibodies (IgG)

With assistance from helper T cells, B cells differentiate into plasma B cells to produce these antibodies against the SARS-CoV-2 antigens.

Antibodies and COVID-19 

References for Antibodies and COVID-19 by journal

A study showed that SARS neutralizing antibodies can successfully block SARS-CoV-2 entry into target cells in vitro, suggesting that the two viruses possess a cross-protective epitope and have similar immune protection against reinfection

SARS neutralizing antibodies and SARS-CoV-2


-  Support for the use of SARS-CoV-2 Ab for therapies
-  Evidence suggesting SARS-CoV-2 Ab may not be the most viable solution

SARS-CoV-2 Antibodies and their uses in future SARS-CoV-2 Therapies

- Type I: only binds to 'up' RBD
- Type II: only binds when at least 2 RBD are 'up'
- Type III: only binds to 'down' RBD
- Type IV: recognizes both 'up' and 'down' RBD
- the image below shows the antibody interactions with RBD to the left and antibodies to the right

Types of Neutralizing Antibodies Targeting SARS-CoV-2 RBD of S protein

- NAbs targeting NTD of spike protein
- NAbs targeting S2 subunit of spike protein

Learn Before

Related

Learn After